Parvizi Murtaza, Kut Engin, Akyol Murat, Ay Semra
Radiation Oncology, Manisa City Hospital, Manisa, TUR.
Medical Oncology, Manisa City Hospital, Manisa, TUR.
Cureus. 2023 Mar 24;15(3):e36635. doi: 10.7759/cureus.36635. eCollection 2023 Mar.
This study aims to identify anxiety and depression caused by adjuvant radiotherapy in breast cancer cases to determine the deterioration in the quality of life and investigate the effect of early treatment.
In this study, the Beck Depression Inventory, Beck Anxiety Inventory, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) Turkish 3.0 forms were evaluated in 63 breast cancer patients before the start of radiotherapy treatment (T1) and at six weeks after the end of radiotherapy treatment (T2).
A high level of anxiety was detected in 77.8% of patients, and depression was found in 25.4% of patients in T1. When depressive cases were evaluated with EORTC QLQ-C30 scores, the general health status ( = 0.043), role function ( = 0.027), emotional ( < 0.002), cognitive ( < 0.001), and social ( < 0.0001) scales were statistically lower in T1, whereas pain ( = 0.045) and insomnia ( < 0.0001) symptoms were higher in T1. Anxiety and EORTC QLQ-C30 scores in terms of emotional function ( = 0.015), social function ( < 0.003), and symptoms of insomnia ( = 0.027) were found to be statistically higher in T1 anxious cases. However, anxiety was detected in only 3% of T2 cases, and no depression was found in any of the cases. Anxiety and EORTC QLQ-C30 scores and symptom scales were evaluated in terms of role function ( < 0.0001), emotional ( = 0.041) and social scales ( = 0.014), fatigue ( = 0.028), pain ( = 0.033), insomnia ( = 0.011), and constipation ( < 0.0001); these were found to be statistically significant in T2.
This study revealed that early diagnosis and treatment of anxiety before initiating adjuvant radiotherapy reduces the development of long-term anxiety-related depression in the future. Therefore, it is recommended that patients be evaluated for anxiety and depression before starting adjuvant radiotherapy.
本研究旨在识别乳腺癌患者辅助放疗引起的焦虑和抑郁,以确定生活质量的恶化情况,并研究早期治疗的效果。
在本研究中,对63例乳腺癌患者在放疗治疗开始前(T1)和放疗治疗结束后六周(T2)进行了贝克抑郁量表、贝克焦虑量表以及欧洲癌症研究与治疗组织生活质量问卷-30(EORTC QLQ-C30)土耳其语3.0版评估。
在T1时,77.8%的患者检测出高度焦虑,25.4%的患者存在抑郁。当用EORTC QLQ-C30评分评估抑郁病例时,T1时的总体健康状况(=0.043)、角色功能(=0.027)、情绪(<0.002)、认知(<0.001)和社会(<0.0001)量表在统计学上较低,而疼痛(=0.045)和失眠(<0.0001)症状在T1时较高。在T1焦虑病例中,焦虑与EORTC QLQ-C30评分在情绪功能(=0.015)、社会功能(<0.003)和失眠症状(=0.027)方面在统计学上较高。然而,在T2病例中仅3%检测出焦虑,且所有病例均未发现抑郁。对焦虑和EORTC QLQ-C30评分及症状量表在角色功能(<0.0001)、情绪(=0.041)和社会量表(=0.014)、疲劳(=0.028)、疼痛(=0.033)、失眠(=0.011)和便秘(<0.0001)方面进行评估;这些在T2时具有统计学意义。
本研究表明,在开始辅助放疗前对焦虑进行早期诊断和治疗可降低未来长期焦虑相关抑郁的发生。因此,建议在开始辅助放疗前对患者进行焦虑和抑郁评估。